Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Current Deferred Revenue (2016 - 2025)

China Pharma Holdings filings provide 16 years of Current Deferred Revenue readings, the most recent being $111580.0 for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 31.21% to $111580.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $111580.0, a 31.21% decrease, with the full-year FY2025 number at $111580.0, down 31.21% from a year prior.
  • Current Deferred Revenue hit $111580.0 in Q4 2025 for China Pharma Holdings, down from $120912.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $572013.0 in Q1 2021 to a low of $24920.0 in Q3 2024.
  • Median Current Deferred Revenue over the past 5 years was $128505.5 (2022), compared with a mean of $194606.1.
  • Biggest five-year swings in Current Deferred Revenue: crashed 85.52% in 2024 and later surged 385.2% in 2025.
  • China Pharma Holdings' Current Deferred Revenue stood at $210028.0 in 2021, then soared by 147.73% to $520295.0 in 2022, then plummeted by 82.6% to $90507.0 in 2023, then skyrocketed by 79.22% to $162208.0 in 2024, then plummeted by 31.21% to $111580.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $111580.0 (Q4 2025), $120912.0 (Q3 2025), and $77683.0 (Q2 2025) per Business Quant data.